伊立替康及卡铂联合紫龙金片一线治疗广泛期小细胞肺癌近期疗效观察

摘要

[目的]观察伊立替康（CPT-11）及卡铂（CBP）联合化疗加紫龙金片一线治疗广泛期小细胞肺癌（smal cel lung cancer, SCLC）的近期疗效及毒副反应。[方法]经病理学或细胞学确诊的初治广泛期SCLC患者42例，KPS评分>60分，随机分为两组进行化疗。治疗组20例：紫龙金片4片，3次/d，伊立替康175 mg/m2 d1，卡铂（AUC=5）d1，静滴，21d为1周期，对照组单用伊立替康加卡铂治疗，2周期后评价疗效。[结果]治疗组有效率与对照组无明显差别，但毒副作用治疗组低于对照组，生活质量改善治疗组优于对照组。[结论]紫龙金能提高小细胞肺癌患者伊立替康联合卡铂化疗期间生活质量，减少化疗毒副作用。%　　[Objective]To evaluate the efficacy,toxicity and side effects of irinotecan and carboplatin plus Zilongjin in the first-line treatment of patients with extensive stage smal cel1 lung cancer(SCLC) .[Methods]42 patients diagnosed as having extensive stage smal-cel lung cancer by pathology or cytology were enrol ed,KPS score>60,the patients were randomly divided into two groups;treatment one 20 cases used irinotecan and carboplatin plus zilongjin, 21 days as cycle,control one 22 cases only used irinotecan and carboplatin. Evaluated after 2 cycles. [Results]Efficiency of the control group had no significant difference from the treatment group, but the side effects of the treatment group were less than the control group, to improve the quality of life in the treatment group was better than the control group.[Conclusion]Zilongjin can improve quality of life and reduce chemotherapy side effects in the patients with smal cel lung cancer who are receiving irinotecan combination carboplatin chemotherapy.